SELLAS Life Sciences (SLS) Payables (2010 - 2026)
SELLAS Life Sciences (SLS) reported Payables of $3.6 million for Q1 2026, down 3.27% year-over-year from $3.8 million in Q1 2025, and up 23.24% on a QoQ basis from $2.9 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Payables data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Payables fell 3.27% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 3.27% YoY) and the FY2025 annual result came in at $2.9 million, down 15.77% from the prior year.
- Payables grew to $3.6 million in Q1 2026 per SLS's latest filing, from $2.9 million in the prior quarter.
- Across five years, Payables topped out at $7.4 million in Q1 2024 and bottomed at $2.1 million in Q3 2022.
- The 5-year median for Payables is $3.5 million (2024), against an average of $3.9 million.
- The widest annual swing landed in 2024, when Payables soared 139.01%; it then slumped 49.31% in 2025.
- Tracing SLS's Payables over 5 years: stood at $3.4 million in 2022, then jumped by 67.98% to $5.6 million in 2023, then tumbled by 37.93% to $3.5 million in 2024, then slipped by 15.77% to $2.9 million in 2025, then advanced by 23.24% to $3.6 million in 2026.
- Per Business Quant, the three latest SLS Payables figures stand at $3.6 million (Q1 2026), $2.9 million (Q4 2025), and $2.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.63 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 3.76 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | 4.55 Mn |
| Jun 30, 2024 | 6.33 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 5.64 Mn |
| Sep 30, 2023 | 4.34 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Mar 31, 2023 | 3.10 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 3.34 Mn |
| Mar 31, 2022 | 2.84 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 2.55 Mn |
| Jun 30, 2021 | 2.28 Mn |
| Mar 31, 2021 | 2.35 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Sep 30, 2020 | 1.78 Mn |
| Jun 30, 2020 | 2.43 Mn |
| Mar 31, 2020 | 2.62 Mn |
| Dec 31, 2019 | 3.90 Mn |
| Sep 30, 2019 | 3.76 Mn |
| Jun 30, 2019 | 3.76 Mn |
| Mar 31, 2019 | 4.64 Mn |
| Dec 31, 2018 | 3.76 Mn |
| Sep 30, 2018 | 7.24 Mn |
| Jun 30, 2018 | 12.10 Mn |
| Mar 31, 2018 | 11.45 Mn |
| Dec 31, 2017 | 11.69 Mn |
| Sep 30, 2017 | 211,000.00 |
| Jun 30, 2017 | 385,000.00 |
| Mar 31, 2017 | 1.16 Mn |
| Dec 31, 2016 | 840,000.00 |
| Sep 30, 2016 | 894,000.00 |
| Jun 30, 2016 | 1.27 Mn |
| Mar 31, 2016 | 1.02 Mn |
| Dec 31, 2015 | 1.60 Mn |
| Sep 30, 2015 | 1.24 Mn |
| Jun 30, 2015 | 2.32 Mn |
| Mar 31, 2015 | 3.29 Mn |
| Dec 31, 2014 | 1.89 Mn |
| Sep 30, 2014 | 3.36 Mn |
| Jun 30, 2014 | 2.04 Mn |
| Mar 31, 2014 | 1.57 Mn |
| Dec 31, 2013 | 2.66 Mn |
| Sep 30, 2013 | 1.89 Mn |
| Jun 30, 2013 | 2.09 Mn |
| Mar 31, 2013 | 2.12 Mn |
| Dec 31, 2012 | 1.98 Mn |
| Sep 30, 2012 | 2.21 Mn |
| Mar 31, 2012 | 2.58 Mn |
| Dec 31, 2011 | 2.66 Mn |
| Sep 30, 2011 | 1.96 Mn |
| Jun 30, 2011 | 1.07 Mn |
| Dec 31, 2010 | 724,000.00 |